Quick Answer
Aquestive Therapeutics, Inc. reported Revenue (ASC 606) of $44.55 million for fiscal year 2025.
Aquestive Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $44.55M | -22.6% |
| 2024 | $57.56M | +13.8% |
| 2023 | $50.58M | +6.1% |
| 2022 | $47.68M | -6.2% |
| 2021 | $50.83M | +10.9% |
| 2020 | $45.85M | -12.8% |
| 2019 | $52.61M | -22.0% |
| 2018 | $67.43M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $12.81M | -5.4% | +28.0% |
| June 30, 2025 | $10.00M | -50.2% | +14.7% |
| March 31, 2025 | $8.72M | -27.7% | -35.6% |
| September 30, 2024 | $13.54M | +4.2% | -32.6% |
| June 30, 2024 | $20.10M | +51.8% | +66.8% |
| March 31, 2024 | $12.05M | +8.3% | -7.3% |
| September 30, 2023 | $13.00M | +13.4% | -1.8% |
| June 30, 2023 | $13.24M | -0.2% | +18.9% |
- Aquestive Therapeutics, Inc. showed a decrease of -22.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2018–2025 period, Aquestive Therapeutics, Inc.’s revenue (asc 606) has declined by 33.9% (from $67.43 million to $44.55 million).
- The most recent figure is from Aquestive Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: